文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

口服胰岛素预防1型糖尿病亲属发病的随机临床试验

Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

该随机临床试验纳入560例自身抗体阳性且糖耐量正常的1型糖尿病患者亲属,随机接受口服胰岛素7.5 mg/d或安慰剂。

要点

  • 主要研究组中口服胰岛素7.5 mg/d与安慰剂相比未显著延迟糖尿病发病时间。
  • 次要分层1中口服胰岛素组发病时间显著长于安慰剂组,但该分层样本量小。
  • 最常见不良事件为感染,口服胰岛素组134例次 vs 安慰剂组120例次,无显著研究相关不良事件。

核心结论

  • 在1型糖尿病患者的自身抗体阳性亲属中,口服胰岛素7.5 mg/d与安慰剂相比未能在2.7年内延迟或预防1型糖尿病发病。
  • 这些发现不支持在本研究使用的方案下将口服胰岛素用于糖尿病预防。

研究设计与样本

  • 随机临床试验,2007年3月2日至2015年12月21日在加拿大、美国、澳大利亚、新西兰、英国、意大利、瑞典、芬兰和德国入组。
  • 纳入至少2种自身抗体(包括胰岛素自身抗体)且糖耐量正常的1型糖尿病患者亲属,共随机560例,随访至2016年12月31日。
  • 主要研究组389例的静脉葡萄糖耐量试验第一时相胰岛素释放高于阈值;次要分层1共55例抗体谱与主要研究组相同但第一时相胰岛素释放低于阈值;次要分层2共114例、分层3共3例抗体谱与第一时相胰岛素释放阈值组合不同。
  • 干预为口服胰岛素7.5 mg/d(n=283)或安慰剂(n=277),主要研究组中口服胰岛素203例、安慰剂186例。

主要发现

  • 主要研究组中位随访2.7年(IQR 1.5-4.6年),口服胰岛素组58例(28.5%)诊断糖尿病,安慰剂组62例(33%)诊断糖尿病。
  • 最常见不良事件为感染(n=254),口服胰岛素组134例次 vs 安慰剂组120例次,无显著研究相关不良事件。

关键数值与推荐

  • 口服胰岛素剂量为7.5 mg/d。

临床怎么用

  • 本研究使用的口服胰岛素7.5 mg/d方案未能延迟或预防1型糖尿病发病,不支持将该方案用于糖尿病预防。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Type 1 diabetes requires major lifestyle changes and carries increased morbidity and mortality. Prevention or delay of diabetes would have major clinical effect. OBJECTIVE: To determine whether oral insulin delays onset of type 1 diabetes in autoantibody-positive relatives of patients with type 1 diabetes. DESIGN, SETTING, AND PARTICIPANTS: Between March 2, 2007, and December 21, 2015, relatives with at least 2 autoantibodies, including insulin autoantibodies and normal glucose tolerance, were enrolled in Canada, the United States, Australia, New Zealand, the United Kingdom, Italy, Sweden, Finland, and Germany. The main study group (n = 389) had first-phase insulin release on an intravenous glucose tolerance test that was higher than the threshold. The 55 patients in the secondary stratum 1 had an identical antibody profile as the main study group except they had first-phase insulin release that was lower than the threshold. Secondary strata 2 (n = 114) and strata 3 (n = 3) had different autoantibody profiles and first-phase insulin release threshold combinations. Follow-up continued through December 31, 2016. INTERVENTIONS: Randomization to receive 7.5 mg/d of oral insulin (n = 283) or placebo (n = 277), including participants in the main study group who received oral insulin (n = 203) or placebo (n = 186). MAIN OUTCOME AND MEASURES: The primary outcome was time to diabetes in the main study group. Significance was based on a 1-sided threshold of .05, and 1-sided 95% CIs are reported. RESULTS: Of a total of 560 randomized participants (median enrollment age, 8.2 years; interquartile range [IQR], 5.7-12.1 years; 170 boys [60%]; 90.7% white non-Hispanic; 57.6% with a sibling with type 1 diabetes), 550 completed the trial including 389 participants (median age, 8.4 years; 245 boys [63%]), 382 (96%) in the main study group. During a median follow-up of 2.7 years (IQR, 1.5-4.6 years) in the main study group, diabetes was diagnosed in 58 participants (28.5%) in the oral insulin group and 62 (33%) in the placebo group. Time to diabetes was not significantly different between the 2 groups (hazard ratio [HR], 0.87; 95% CI, 0-1.2; P = .21). In secondary stratum 1 (n = 55), diabetes was diagnosed in 13 participants (48.1%) in the oral insulin group and in 19 participants (70.3%) in the placebo group. The time to diabetes was significantly longer with oral insulin (HR, 0.45; 95% CI, 0-0.82; P = .006). The HR for time to diabetes for the between-group comparisons for the 116 participants in the other secondary stratum was 1.03 (95% CI, 0-2.11; P = .53) and for the entire cohort of 560 participants was 0.83 (95% CI, 0-1.07; P = .11), which were not significantly different. The most common adverse event was infection (n = 254), with 134 events in the oral insulin group and 120 events in the placebo group, but no significant study-related adverse events occurred. CONCLUSIONS AND RELEVANCE: Among autoantibody-positive relatives of patients with type 1 diabetes, oral insulin at a dose of 7.5 mg/d, compared with placebo, did not delay or prevent the development of type 1 diabetes over 2.7 years. These findings do not support oral insulin as used in this study for diabetes prevention. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00419562.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Krischer JP, Schatz DA, Bundy B, et al. Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2017. PMID: 29164254. doi:10.1001/jama.2017.17070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。